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Abstract
Background: The diagnostic value and prognostic significance of circulating tumor cell (CTC) detection in patients
with bladder cancer is controversial. We performed a meta-analysis to consolidate current evidence regarding the
use of CTC detection assays to diagnose bladder and other urothelial cancers and the association of CTC positivity
with advanced, remote disease.
Methods: Studies that investigated the presence of CTCs in the peripheral blood of patients with bladder cancer
and/or urothelial cancer were identified and reviewed. Sensitivities, specificities, and positive (LR+) and negative
likelihood ratios (LR-) of CTC detection in individual studies were calculated and meta-analyzed by random effects
model. Overall odds ratio of CTC positivity in patients with advanced disease versus those with organ-confined
cancer was also calculated.
Results: Overall sensitivity of CTC detection assays was 35.1% (95%CI, 32.4-38%); specificity, LR+, and LR- was 89.4%
(95%CI, 87.2-91.3%), 3.77 (95%CI, 1.95-7.30) and 0.72 (95%CI, 0.64-0.81). CTC-positive patients were significantly more
likely to have advanced (stage III-IV) disease compared with CTC-negative patients (OR, 5.05; 95%CI, 2.49-10.26).
Conclusions: CTC evaluation can confirm tumor diagnosis and identify patients with advanced bladder cancer.
However, due to the low overall sensitivity, CTC detection assays should not be used as initial screening tests.
Background
Bladder cancer is an important cause of morbidity and
mortality with an estimated 386,300 new cases and
150,200 deaths occurring worldwide in 2008 alone [1].
The highest bladder cancer incidence rates are reported
in Europe, North America, and Northern Africa and the
majority of cases occur in men [1,2]. Urothelial (transi-
tional cell) carcinomas are the most common histologi-
cal type of bladder cancer. Non-urothelial vesical
tumors are extremely rare and account for < 5% of all
primary bladder malignancies combined [3]. Approxi-
mately 95% of primary urothelial cell cancers arise from
the bladder and only a few cases originate from other
sites within the urinary tract such as the renal pelvis
and ureter [4-6].
The most widely used system for bladder cancer sta-
ging at this time is the American Joint Committee on
Cancer (AJCC) tumor, lymph node, and hematogenous
metastasis (TNM) system [7]. According to this system,
extravesical disease is categorized as either stage III or
IV tumors invading adjacent tissues and/or metastasiz-
ing to lymph nodes or to distant sites, whereas stage ≤II
cancers are localized (organ-confined). However, initial
clinical staging can be imprecise and a considerable pro-
portion of patients thought to have localized disease will
be upstaged to extravesical cancer following surgical
treatment [8]. Inaccurate clinical staging may lead to
suboptimal treatment, particularly since extravesical dis-
ease at the time of surgical therapy is a known predictor
of poor prognosis [9,10] and patients who are thought
to have localized disease may not receive potentially
beneficial neoadjuvant therapy. Increased accuracy of
initial clinical staging would thus facilitate risk stratifica-
tion and preoperative decision making.
* Correspondence: msaouel@gmail.com
1Department of Experimental Physiology, Medical School, National and
Kapodistrian University of Athens, 75 Micras Asias str., Goudi-Athens 115 27,
Greece
Full list of author information is available at the end of the article
Msaouel and Koutsilieris BMC Cancer 2011, 11:336
http://www.biomedcentral.com/1471-2407/11/336
© 2011 Msaouel and Koutsilieris; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.During the initial sequences of metastatic progression,
cancer cells originating from the primary site intravasate
into the lymphatics and systemic circulation as circulat-
ing tumor cells (CTCs) [11,12]. Although the majority
of CTCs will either die in the bloodstream due to
mechanical shear forces, immune surveillance, and/or
other regulatory mechanisms, a few cells will success-
fully extravasate and form new colonies at distant sites.
A variety of methods for detecting CTCs have been
developed including nested RT-PCR, which utilizes two
pairs of PCR primers to amplify a single locus. PCR-
based methods are considered highly sensitive and also
to demonstrate strong specificity via the design of pri-
mers that detect mRNA expression of tumor-specific
g e n e ss u c ha sc y t o k e r a t i n( C K ) - 2 0 ,u r o p l a k i n( U P )I I ,
and epidermal growth factor receptor (EGFR) [13,14].
The CellSearch system is another commonly used tech-
nique that was recently approved by the US Food and
Drug Administration (FDA) for CTC detection in
patients with metastatic breast, colorectal, and prostate
cancer. CellSearch is a semi-automated, standardized,
enrichment and detection system that uses magnetically
labeled anti-EpCAM antibodies to capture CTCs that
are then visualized and enumerated by digital fluores-
cent microscopy [15].
The presence of CTCs in the circulation may signify
an early step of the metastatic process, which may be
followed by establishment of clinically undetectable
micrometastatic foci that will ultimately grow into clini-
cally apparent metastasis. However, clinical reports eval-
uating molecular detection of CTCs have given
contradictory and inconclusive results with some studies
indicating that CTC detection may be associated with
higher-stage disease [16-22] whereas others failed to
show such an association [23-27]. We used meta-analy-
tic approaches to pool together and summarize quanti-
tatively the available evidence with regards to diagnostic
accuracy of CTC detection in bladder and urothelial
cancer patients as well as clarify whether detection of
these cells is associated with higher stage, non-organ-
confined disease.
Methods
Publication Search
We conducted a computerized search in April 2011 (last
search, April 18 2011) without time restrictions using
the electronic databases PubMed, SciVerse Scopus, Goo-
gle Scholar, and the World Health Organization (WHO)
International Clinical Trials Registry Platform. The
search strategy included the following keywords variably
combined: “bladder cancer,”“ circulating tumor cells,”
“circulating urothelial cells,”“ circulating bladder cancer
cells,”“ minimal residual disease,”“ peripheral blood,”
“serum,”“ polymerase chain reaction,”“ immunomagnetic
cell enrichment,”“ CellSearch,”“ CK19/CK20/uroplakin/
EGFR/survivin mRNA,”“ micrometastasis,”“ urothelial
cancer,”“ transitional cell cancer,”“ molecular staging,”
and “bladder cancer cell enrichment.” We evaluated all
associated publications to retrieve the most eligible stu-
dies. Moreover, their reference lists were searched
manually to find other relevant publications. Both origi-
nal and review articles were sought because the latter
were considered an additional source of unaccounted
original works.
Inclusion and Exclusion Criteria
Eligibility criteria for further meta-analysis of the studies
included: 1) publication in a peer-reviewed journal; 2)
primary cohort of patients with bladder cancer and/or
urothelial cancer originating from other locations (ani-
mal models or in vitro cell line studies were excluded);
and 3) clearly identified negative controls (healthy
volunteers, nonmalignant bladder disease patients, or
patients with prior history of urothelial cancer but no
evidence of recurrence) and/or sufficient data to extra-
polate the AJCC stage of the patients. Major exclusion
criteria were the number of patients enrolled–there had
to be ≥20 patients or ≥30 patients and controls for a
s t u d yt ob ec o n s i d e r e de l i g i b l e –and duplication of
results from a previous publication. Duplicate popula-
tions were included in the analysis only if they were
investigated with multiple molecular methods and/or
tumor markers. Data from letters to the editor, meetings
abstracts, preliminary reports, and non-English language
papers were not considered eligible.
Data Extraction
The two investigators independently reviewed and
extracted the following data from all eligible publica-
tions according to the inclusion and exclusion criteria:
first author’s surname, year of publication, country of
origin, study population characteristics (including no.
patients enrolled, age, source of the control groups and
cancer stages with distribution of patients among
stages), outcomes measured (diagnostic accuracy, corre-
lation with stage, recurrence-free survival, and overall
survival), sampling site (peripheral blood, bone marrow,
lymph nodes, tumor tissue biopsies), timing of blood
withdrawal (preoperative, intraoperative, postoperative,
before, during, or after chemotherapy), blood sample
volume, no. blood samples per patient, method of CTC
isolation and enrichment, molecular technique, target
gene, and/or antigen used for CTC detection, in vitro
sensitivity of each molecular method (if assessed), and
no. subjects found CTC positive (CTC+) or negative
(CTC-) using each molecular method. In cases where
multiple blood samples were collected, CTC status of
the preoperative (pretreatment) sample was used in the
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ple was analyzed per patient, we considered as CTC+
those cases where at least one pretreatment sample/ana-
lysis was positive. Disagreements were resolved by itera-
tion, discussion, and consensus between the two
authors.
Statistical Analysis
Statistical pooling of diagnostic accuracy variables (sen-
sitivity, specificity, likelihood ratios) was performed
using Meta-DiSc software (Version 1.4) [28]. Potential
variations due to threshold effect were assessed graphi-
cally by visual inspection of accuracy estimates pairs in
forest plots and sROC curves as well as statistically by
computing the Spearman correlation coefficient between
the logit of sensitivity and the logit of 1 - specificity
[28,29]. The positive likelihood ratio (LR+) was defined
as percent bladder cancer patients (and/or patients with
urothelial cancer in other locations within the urinary
tract) who had positive CTC detection (CTC+) divided
by that of control subjects who were CTC+. The nega-
tive likelihood ratio (LR-) was defined as percent blad-
der and urothelial cancer patients with CTC-negative
results (CTC-) divided by that of control subjects who
were CTC-. To assess between-study heterogeneity
(other than threshold effect) and between-study incon-
sistency Cochran Q statistic and inconsistency index (I
2)
were calculated and the level of significance for the cor-
responding P-value was set at P = 0.10. Due to antici-
pated interstudy heterogeneity, a random effects analysis
model (DerSimonian Laird) [30] was applied in all
meta-analytic calculations performed because it provides
more conservative estimates of the pooled data. Pooling
of individual studies to calculate odds ratios (OR) of
CTC positivity in patients with extra-organ and/or
lymph node-positive and metastatic disease (stage III-IV
patients) compared with those with organ-confined can-
cer (stage ≤ II) was performed using the MIX 2.0 Pro
software (version 2.0.1.2) [31]. Publication bias was
assessed by visual inspection of the funnel plot [32] and
statistically using Egger’s linear regression test [33]. To
be more conservative the level of statistical significance
for the interpretation of Egger’s test was set at P = 0.10.
In cases of cells containing zero values for no. events of
interest, continuity correction was implemented by addi-
tion of 0.5. To assess stability of the meta-analyses’
results one-way sensitivitya n a l y s i sw a sp e r f o r m e db y
omitting each study (one at a time) from the meta-ana-
lysis. In cases were studies evaluated multiple markers
independently we combined the data of each assay sepa-
rately following the approach used in a recent meta-ana-
lysis of CTCs in breast cancer [34]. Because this strategy
may compromise interstudy independence, sensitivity
analyses to assess its statistical effect on our model were
performed by including the re s u l t so fas i n g l em a r k e r
for each study using either the marker with the best
specificity or the best sensitivity (in cases were specifi-
city was equal between markers). To evaluate the effects
of potential sources of heterogeneity in the pooled cal-
culations subgroup analysis was performed considering
more homogenous set of studies that adopted similar
design variables. Subgroups were constructed only when
≥3 studies could be included. Tests of interaction were
performed to assess differences between subgroups [35].
Values of 95% confidence intervals (CI) were used for
all pooled data; all P-values are two tailed and those <
0.05 were considered statistically significant unless
otherwise specified. To correct for multiplicity of com-
parisons in subgroup analyses, P-values of paired com-
parisons between subgroups were adjusted by
Bonferroni-Holm procedure [36].
Results
Search Results
The study flowchart is illustrated in Figure 1. The
search criteria yielded 158 abstracts of which 119 were
Figure 1 Study flowchart of selection of eligible studies
included in the meta-analyses computations.
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bladder cancer. Twenty-nine relevant studies were iden-
tified [16-27,37-53] and reviewed in detail. Eight of
these studies did not meet the inclusion criteria: 3 stu-
dies had enrolled < 20 patients or < 30 patients and
controls [17,46,47]; 2 were not written in English
[52,53], 1 [51] reported follow-up data from a patient
cohort originally assessed in a previous report [50]; 1
article did not include controls in the study design and
all enrolled patients had stage IV urothelial cancer [44];
and 1 article was a case report of 2 patients with meta-
static urothelial cancer [42]. Therefore 28 articles were
included in further meta-analysis calculations: 18 articles
[16,19-21,23-25,27,37-41,43,45,48-50] were included the
meta-analysis of diagnostic accuracy of CTC detection
(combined total of 764 patients and 708 controls) and
12 articles [16,18-20,22-26,39,41,50] were included in
the meta-analysis of CTC association with disease stage
(combined total of 331 patients with stage ≤II cancer
and 203 with advanced-stage III-IV cancer).
Baseline characteristics of identified studies
Patients’ baseline characteristics and study design vari-
ables of the included articles are summarized in Table 1
and Additional file 1, respectively. Mean no. patients
enrolled was 41 (range, 4-108) with 7 of 21 studies
(33.3%) enrolling > 50 patients. Considering the 18 stu-
dies that compared CTC presence among patients and
control groups, mean no. control subjects was 39 (range
2-344). Tumor histology was reported in 14 of 21 stu-
dies (66.7%). All patients in these 14 studies were diag-
nosed with transitional cell carcinoma with 2 patients in
one study [19] showing additional squamous and adeno-
carcinoma components, respectively. Cancer originated
from the bladder in 829 of 869 cases (95.4%), bladder
and ureter in 1 of 869 cases (0.12%), upper urinary tract
(renal pelvis and ureter) in 38 of 869 cases (4.4%), and
urethra in 1 of 869 cases (0.12%).
Peripheral blood samples were collected before any
treatment in 11 of 21 studies (52.4%), before therapy or
≥7 days postchemotherapy in 2 of 21 studies (9.5%)
whereas 8 of 21 studies (38.1%) used miscellany sam-
pling schedules or did not report the sample collection
timing. Mean volume of analyzed blood samples was 8.6
(range, 2-16) ml with 10 of 21 (47.6%) studies using
≤7.5 ml blood for their assays. Six of 21 studies (28.6%)
collected two consecutive blood samples, processing
only the second tube and discarding the first tube to
avoid contamination by Merkel cells. With regards to
CTC enrichment from peripheral blood samples 6 of 21
studies (28.6%) used Ficoll-Hypaque centrifugation, 2
studies (9.5%) included further enrichment methods in
addition to Ficoll-Hypaque centrifugation, 2 studies
(9.5%) used guanidinium thiocyanate-phenol-chloroform
extraction, 3 studies (14.3%) adopted red blood cell lysis
protocols, 1 study (4.8%) used succinyl-linked gelatin
separation, 5 studies (23.8%) used the CellSearch system
to enrich and detect CTCs, and 1 study (4.8%) applied a
different immunomagnetic technique. One study (4.8%)
did not report a cell enrichment method.
CTC detection was based on PCR in 13 of 21 studies
(61.9%), of which nested RT-PCR was the most fre-
quently used (9 of 13 studies) whereas single-round
PCR was used in 4 studies, two of which were enhanced
with either Southern blot analysis (1 study) or immuno-
bead isolation (1 study). Five of 21 studies (23.8%) used
the CellSearch system for CTC detection, 2 studies
(9.5%) used immunocytochemistry-based methods, and
1 study (4.8%) used an ELISA-based telomerase assay.
Among the PCR-based methods, 8 of 13 studies (61.5%)
evaluated 1 marker using RT-PCR-based techniques
whereas 4 of 13 (30.8%) studies assessed mRNA expres-
sion of ≥2 different markers in the same patient and
control populations. Only two of these studies [45,50]
additionally provided data on multiple marker combina-
tion in bladder cancer patients whereas the other two
studies [37,39] reported the presence of each marker
individually. One study [48] defined CTCs as cells lack-
ing CD45 mRNA but expressing CD8 mRNA (CD45
-/
CD8
+ by PCR detection) and we maintained this defini-
tion when analyzing data from that report. The most
commonly used marker for PCR-based techniques was
CK-20 (evaluated in 7 of 13 studies; 53.8%) followed by
UP II (5 of 13 studies; 38.4%) and EGFR (3 of 13 stu-
dies; 23.1%) whereas tenascin C, MUC7, UP Ia, UP Ib,
UP III, and CK-19 were evaluated in 1 of 13 (7.7%) stu-
dies each.
In vitro sensitivity of circulating bladder/urothelial
cancer cell detection methods was reported in 11 of 21
studies (52.4%) (Additional file 1). In 9 of 11 studies
(81.8%) it was determined by spiking experiments that
1-10 bladder cancer cells could be detected in 10
6 nor-
mal cells (or cells not expressing the tumor marker) or
in 5 ml blood. Two of 11 studies (18.2%) used the Cell-
Search system and reported a mean recovery rate of
85.5% (range, 78.5-94%) in 7.5-10 ml blood.
CTC Diagnostic Value
When all eligible studies and assays were pooled into
the diagnostic accuracy meta-analysis, the overall sen-
sitivity of CTC detection was 35.1% (95%CI, 32.4-38%;
I
2 = 86.7%; Figure 2A); overall specificity LR+, and LR-
was 89.4% (95%CI, 87.2-91.3%; I
2 = 89.1%; Figure 2B),
3.77 (95%CI, 1.95-7.30; I
2 =8 7 . 8 % ;F i g u r e2 C ) ,a n d
0.72 (95%CI, 0.64-0.81; I
2 = 79.6%; Figure 2D). The
included studies were significantly heterogenous in
their estimates of sensitivity, specificity, LR+, and LR-
(all Q statistic P < 0.001; all I
2 > 75%). Threshold
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First author
(year of
publication)
(reference)
Country
of origin
CTC+ patients
(marker used)
CTC+ controls (marker used) Patient age (years) Tumor
histology
Tumor
location
Tumor
stage
(AJCC)
Rate of CTC+
stage ≤II pts
(marker
used)
Rate of CTC+
stage III-IV
pts
(Marker used)
Median (range) Mean (range)
Gazzaniga
(2005)[37]
Italy 11/19 (Tenascin C),
11/19 (EGFR)
0/40 (Tenascin C)
0/40 (EGFR)
NR NR NR B I-IV NR NR
Ribal (2006)
[23]
Spain 23/70 0/22 65 (44-81) - TCC B 0a-IV 4/31 17/39
Champelovier
(1999)[38]
France 3/4 21/29 NR NR NR B NR NR NR
Okegawa
(2004)[39]
Japan 25/108 (UP II), 31/
108 (CK-20)
Healthy volunteers: 0/20 for
either marker; nonmalignant
bladder disease patients: 0/10 for
UP II and 2/10 for CK-20
Bladder cancer and
nonmalignant bladder
patients: 57 (42-75);
healthy volunteers: 41
(21-52)
- TCC B 0a-IV 20/91 (CK-20)
14/91 (UP II)
11/17 (CK-20)
11/17 (UP II)
Retz (2001)[24] Germany 2/20 0/10 (isolated PBMN) (34-79) - NR B 0a-IV 0/14 2/6
Gudemann
(2000)[16]
Germany 12/49 Healthy volunteers: 0/22;
urocystitis patients: 0/6; benign
renal tumor patients: 0/6;
patients with prior history of
urothelial cancer but no
evidence of recurrence: 0/4
Cancer patients: 68 (60-
75); urocystitis patients: 72
(68-74)
- TCC B: 48/49
U/P: 1/
49
0a-IV 5/35 7/14
Li (1999)[40] U.S.A. 3/60 0/10 NR NR TCC B NR NR NR
Soria (2002)
[25]
France 27/30 0/17 Patients: 68.5 (49-99);
controls: (26-58)
- NR B 0-IV 14/15 13/15
Desgrandchamps
(1999)[41]
U.K. 1/31 0/2 (initially
thought to have
malignant bladder
disease, one
patient was found
to have
nonspecific
inflammation and
one
schistosomiasis)
NR NR TCC B 0a-IV
0/25 1/6
Naoe (2007)
[18]
Japan 8/26 No controls assessed 70.5 (55-85) - TCC B: 22/26
U: 3/26
P: 1/26
0a-IV 0/8 8/18
Kinjo (2004)
[19]
Japan 18/38 0/18 (UTI n = 6; BPH n = 7;
other benign conditions n = 5)
Cancer patients: 67 (35-
87); controls:56 (18-78)
- TCC:36/38;
TCC+sq:1/
38; TCC
+ad:1/38
B 0a-IV 13/33 5/5
Guzzo (2009)
[26]
U.S.A. 9/43 No controls assessed - 67.5 (46-83) TCC B 0a-IV 2/17 7/26
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4Table 1 Baseline characteristics of patients in the 21 eligible studies included in the meta-analyses (Continued)
Allard (2004)
[43]
U.S.A. 6/7 8/145 healthy pre- and post-
menopausal women had 1 CTC;
14/199 women with benign
breast diseases had 1 CTC (none
had ≥2 CTCs)
NR NR NR B IV NR NR
Lu (2000)[20] Japan 15/56 0/10 healthy volunteers; 0/10
patients with renal cell cancer
71.5 (35-87) 69.41 TCC B: 42/56
B/U: 1/
56
U: 9/56
P: 4/56
0a-IV 4/34 11/22
Osman (2004)
[45]
U.S.A. 21/48 (UP Ia), 10/48
(UP Ib), 25/48 (UP II),
11/48 (UP III), 26/48
(EGFR)
a
5/14 (UP Ia), 7/14 (UP Ib), 5/14
(UP II), 10/14 (UP III), 10/14
(EGFR)
a
64 (42-88) - NR B III-IV NR NR
Rink (2011)[27] Germany 20/55 1/10 Patients: 67 (44-89);
healthy volunteers: 45
Patients:66;
healthy
volunteers: 46
TCC B 0a-IV NR NR
Fujii (1999)[21] Japan 9/40 0/25 NR NR TCC B: 27/40
U/P: 12/
40
Urethra:
1/40
0a-IV NR NR
Okegawa
(2010)[22]
Japan 11/36 No controls assessed Stages I-II patients: 71;
stage III-IV patients: 68
- TCC B: 28/36
U/P: 8/
36
I-IV 0/16 11/20
Gradilone
(2010)[48]
Italy 24/54 (CD45-/CK8+),
22/54 (survivin)
0/20 57.5 (51-64) - NR B I NR NR
Meye (2002) Germany 18/34 0/20 NR NR TCC B NR NR NR
Gazzaniga
(2001)[50]
Italy 20/27 (EGFR); 17/27
(UP II); 11/27 (CK-
19); 4/27 (CK-20)
Healthy volunteers: 0/30 (EGFR),
0/30 (UP II), 6/30 (CK-19), 4/30
(CK-20); cystitis patients: 0/9
(EGFR), 3/9 (UP II), 3/9 (CK-19), 2/
9 (CK-20)
NR NR TCC B Oa-IV 2/8 (EGFR)
7/8 (UP II)
1/8 (CK-19)
1/8 (CK-20)
18/19 (EGFR)
3/19 (UP II)
10/19 (CK-19)
3/19 (CK-20)
aBladder cancer patients in this study were defined as those with disease at the end of follow up; controls were defined as those without disease at end of follow up
B, bladder; BPH, benign prostatic hyperplasia; CK, cytokeratin; CTC+, circulating tumor cell positive; EGFR, epidermal growth factor receptor; NR, not reported/retrievable; P, renal pelvis; PBMN, peripheral blood
mononucleocytes; pts, patients; TCC, transitional cell cancer; TCC+ad, transitional cell cancer with adenocarcinoma component; TCC+sq, transitional cell cancer with squamous component; U, ureter; UP, uroplakin;
UTI, urinary tract infection.
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4effect was not detected (Spearman r = -0.115; P =
0.567). The stability of our model was confirmed by
leave-one-out sensitivity analysis, which generated
pooled estimates very close to those obtained with all
eligible studies (mean sensitivity [range], 35.2%, 33.7-
36.8%; mean specificity [range], 89.4%, 87-91.3%; mean
LR+ [range], 3.79, 3.44-4.25; mean LR- [range] 0.72,
0.70-0.74). Single-marker sensitivity analysis of the 18
studies, estimated by using only the most specific (or
most sensitive in cases with equal specificity) assay to
define CTC positivity in each study, showed a pooled
sensitivity 34.9% (95%CI, 31.5-38.5%; I
2 =8 9 . 3 % ) ,s p e -
cificity 93.1% (95%CI, 91.0-94.8%; I
2 =8 7 . 3 % ) ,L R +
7.17 (95%CI, 3.032-16.943; I
2 = 78.4%;), and LR-0.66
(95%CI, 0.56-0.78; I
2 = 85.9%;).
The results of subgroup analyses are summarized in
Table 2. Studies conducted in Italy showed significantly
higher sensitivity compared with those conducted in
Germany (adjusted P = 0.0099), Japan (adjusted P <
0.001), and the USA (adjusted P = 0.0033). Studies con-
ducted in the USA also showed significantly lower speci-
ficity compared with those conducted in Italy or Japan
(adjusted P < 0.001). Studies conducted in countries
o t h e rt h a nG e r m a n y ,I t a l y ,J a p a n ,o rt h eU S As h o w e d
significantly lower specificity compared with those origi-
nating from Germany (adjusted P < 0.001), Italy
(adjusted P < 0.001), Japan (adjusted P < 0.001), or the
USA (adjusted P = 0.0015). Studies that did not report
the histological type of the cancer had significantly
higher sensitivity and specificity compared with those
Figure 2 Diagnostic accuracy forest plots. Forest plots of the overall sensitivity (A),s p e c i f i c i t y(B), positive likelihood ratio (LR+) (C),a n d
negative likelihood ratio (LR-) (D) of circulating tumor cell detection are presented. The size of each square is proportional to sample size.
Horizontal lines in each square show the corresponding 95% confidence intervals (CI). The center of the diamond indicates the overall sensitivity,
specificity, LR+, and LR- and the ends correspond to 95%CI.
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Parameter Subgroups
a Sensitivity
b Specificity
b Positive likelihood
ratio
b
Negative
likelihood ratio
b
Country of origin Germany (n = 4) 32.9% (25.7 to
40.8%; I
2 = 77.8%)
98.7% (93.1 to
100%; I
2 = 28.6%)
6.86 (1.99 to 23.63;
I
2 =0 )
0.72 (0.57 to 0.92;
I
2 = 75.1%)
Italy (n = 3) 55.0% (44.7 to
65.0%; I
2 = 70.0%)
100% (96.3 to
100%; I
2 =0 )
37.15 (7.53 to
183.47; I
2 =0 )
0.43 (0.26 to 0.71;
I
2 = 74.7%)
Japan (n = 4) 27.7% (22.1 to
33.8%; I
2 = 64.1%)
100% (96.1 to
100%; I
2 =0 )
13.79 (3.45 to 55.22;
I
2 =0 )
0.74 (0.65 to 0.83;
I
2 = 47.8%)
USA (n = 3) 29.6% (21.4 to
38.8%; I
2 = 95.4%)
92.7% (89.5 to
95.1%; I
2 = 82.2%)
3.25 (0.27 to 38.72;
I
2 = 95.4%)
0.60 (0.18 to 1.97;
I
2 = 93.4%)
Other (n = 4) 40.0% (31.7 to
48.8%; I
2 = 95.0%)
70.0% (57.9 to
80.4%; I
2 = 94.2%)
3.34 (0.11 to 104.66;
I
2 = 90.6)
0.55 (0.22 to 1.38;
I
2 = 89.0%)
Histologic tumor type TCC ± other components (n = 11) 28.9% (25.2 to
32.8%; I
2 = 87.5%)
99.6% (97.6 to
100%; I
2 =0 )
8.42 (3.5 to 20.29; I
2
= 15.6%)
0.71 (0.61 to 0.83;
I
2 = 82.1%)
Not reported (n = 7) 53.8% (46.3 to
61.2%; I
2 = 85.7%)
89.9% (86.8 to
92.4%; I
2 = 93.7%)
5.89 (1.61 to 21.62;
I
2 = 89.2%)
0.49 (0.28 to 0.85;
I
2 = 89.2%)
Sampling time Pretreatment or ≥7 days post-
chemotherapy (n = 11)
31.0% (27.0 to
35.2%; I
2 = 50.0%)
95.8% (93.8 to
97.4%; I
2 = 53.1%)
11.57 (7.28 to 18.40;
I
2 = 1.3%)
0.71 (0.62 to 0.81;
I
2 = 71.2%)
NR or miscellany (n = 7) 43.2% (36.9 to
49.7%; I
2 = 93.8%)
83.1% (76.2 to
88.7%; I
2 = 93.1%)
5.69 (1.16 to 27.97;
I
2 = 86.7%)
0.52 (0.30 to 0.89;
I
2 = 94.2%)
Blood sample volume ≤7.5 ml (n = 8) 31.3% (26.6 to
36.4%; I
2 = 89.2%)
88.8% (83.5 to
92.8%; I
2 = 92.8%)
8.16 (1.17 to 56.83;
I
2 = 85.8%)
0.64 (0.49 to 0.85;
I
2 = 89.7%)
> 7.5 ml (n = 10) 38.4% (33.5 to
43.5%; I
2 = 89.9%)
94.7% (92.4 to
96.5%; I
2 = 69.6%)
7.15 (2.52 to 20.32;
I
2 = 71.2%)
0.67 (0.54 to 0.83;
I
2 = 82.4%)
Collection of two
consecutive blood samples
Yes (n = 6) 41.2% (35.2 to
47.5%; I
2 = 90.3%)
100% (97.1 to
100%; I
2 =0 )
15.32 (4.91 to 47.84;
I
2 =0 )
0.61 (0.46 to 0.81;
I
2 = 87.6%)
No (n = 12) 31.6% (27.6 to
36.0%; I
2 = 89.0%)
91.6% (89.0 to
93.7%; I
2 = 90.3%)
5.33 (1.93 to 14.68;
I
2 = 83.0%)
0.69 (0.56 to 0.85;
I
2 = 85.4%)
Cell separation method Ficoll-Hypaque centrifugation ±
further methods (n = 8)
34.4% (29.2 to
39.9%; I
2 = 90.5%)
87.9% (82.0 to
92.3%; I
2 = 92.5%)
6.99 (0.88 to 55.73;
I
2 = 85.9%)
0.69 (0.56 to 0.84;
I
2 = 76.8%)
RBC lysis protocols (n = 3) 35.1% (28.4 to
42.2%; I
2 = 87.0%)
91.9% (82.2 to
97.3%; I
2 = 87.9%)
5.74 (0.50 to 65.75;
I
2 = 75.8%)
0.69 (0.52 to 0.91;
I
2 = 66.4%)
Other protocols or NR (n = 7) 35.5% (29.5 to
41.9%; I
2 = 91.3%)
95.1% (92.8 to
96.9%; I
2 = 56.8%)
10.77 (4.92 to 23.56;
I
2 = 19.9%)
0.57 (0.36 to 0.92;
I
2 = 94.3%)
Molecular detection
technique
RT-PCR based (including nested
RT-PCR; n = 13)
32.0% (28.3 to
36.0%; I
2 = 85.8%)
91.7% (88.1 to
94.5%; I
2 = 90.6%)
7.75 (2.38 to 25.24;
I
2 = 80.2%)
0.70 (0.61 to 0.81;
I
2 = 81.8%)
Other (n = 5) 45.9% (37.9 to
54.0%; I
2 = 93.7%)
94.1% (91.3 to
96.3%; I
2 = 22.2%)
7.60 (2.17 to 26.67;
I
2 = 53.3%)
0.45 (0.22 to 0.94;
I
2 = 89.4%)
Nested RT-PCR method Yes (n = 9) 30.5% (26.2 to
35.1%; I
2 = 71.6%)
87.4% (82.1 to
91.6%; I
2 = 92.3%)
5.37 (1.58 to 18.27;
I
2 = 77.7%)
0.76 (0.70 to 0.82;
I
2 = 24.7%)
No (n = 9) 41.0% (35.5 to
46.6%; I
2 = 93.4%)
95.4% (93.2 to
97.1%; I
2 = 52.1%)
10.08 (3.90 to 26.08;
I
2 = 43.1%)
0.49 (0.29 to 0.81;
I
2 = 94.2%)
PCR marker used
c CK-20 (n = 7) 26.4% (21.7 to
31.6%; I
2 = 48.8%)
85.0% (79.1 to
89.7%; I
2 = 92.6%)
3.38 (0.99 to 11.59;
I
2 = 74.5%)
0.80 (0.73 to 0.89;
I
2 = 43.1%)
UP II (n = 5) 28.4% (23.4 to
33.9%; I
2 = 91.9%)
92.9% (86.5 to
96.9%; I
2 = 78.2%)
4.15 (1.20 to 14.33;
I
2 = 62.8%)
0.75 (0.59 to 0.95;
I
2 = 85.2%)
EGFR (n = 3) 60.6% (50.0 to
70.6%; I
2 = 34.4%)
89.2% (81.1 to
94.7%; I
2 = 95.7%)
11.94 (0.03 to
4369.8; I
2 = 96.2%)
0.54 (0.23 to 1.28;
I
2 = 81.1%)
Other (n = 6) 36.0% (29.7 to
42.6%; I
2 = 69.4%)
77.7% (69.9 to
84.3%; I
2 = 90.2%)
1.48 (0.47 to 4.65; I
2
= 88.0%)
0.87 (0.56 to 1.35;
I
2 = 81.7%)
aPooled analysis performed by including results of single marker (either the most specific or the most sensitive in cases with equal specificity) in cases where
multiple markers were assessed per study.
bData in parentheses are 95% confidence intervals.
cSubgroup analyses of the different tumor markers used in PCR-based methods included and compared data from all markers in those studies where multiple
assays were used.
NR, not reported/retrievable; RBC, red blood cells; TCC, transitional cell cancer.
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Page 8 of 14that reported this parameter (adjusted P < 0.001).
Furthermore, studies in which blood samples were col-
lected either before treatment or ≥7 days after the last
chemotherapy cycle demonstrated significantly lower
sensitivity (adjusted P = 0.025) but higher specificity
(adjusted P < 0.001) compared with those with other
timeframes.
Higher blood sample volume was significantly asso-
ciated with increased sensitivity (adjusted P = 0.03)
and specificity (adjusted P < 0.001). Collection of two
consecutive blood samples and processing of the sec-
ond tube only so as to avoid Merkel cell contamination
demonstrated significantly higher specificity (adjusted
P < 0.001) and no significant difference of sensitivity
(adjusted P = 0.127) versus single blood sample collec-
tion. No significant difference of diagnostic accuracy
variables was detected between cell separation method
subgroups. RT-PCR-based techniques demonstrated
significantly lower sensitivity (adjusted P = 0.03) and
no significant difference of specificity (adjusted P >
0.2) compared with other molecular detection meth-
ods. Nested RT-PCR also showed significantly lower
sensitivity (adjusted P = 0.046) and specificity (adjusted
P = 0.0022) compared with other PCR-based and non-
PCR-based CTC detection techniques. PCR-based tests
assessing expression of EGFR yielded significantly
higher overall sensitivity compared with CK-20
(adjusted P < 0.001), UP II (adjusted P < 0.001), and
all other markers included in the meta-analysis
(adjusted P < 0.001). In addition, UP II showed signifi-
cantly higher overall specificity (adjusted P = 0.0048)
compared with the other markers (except EGFR and
CK-20). No significant difference of LR+ and LR- was
detected in tests of interaction between the subgroups
(all adjusted P > 0.05).
Association of CTC detection with disease stage
Statistical pooling of all eligible studies and assays
demonstrated that CTC+ patients were significantly
more likely to have advanced (stage III-IV) disease com-
pared with CTC- patients (OR, 5.05; 95%CI, 2.49-10.26).
ORs and 95%CIs from individual studies as well as the
pooled calculations are shown in Figure 3A. Moderate
heterogeneity among the studies was detected (Q statis-
tic P = 0.0076; I
2 = 52.3%). No significant publication
bias was detected as suggested by funnel plot inspection
and Egger’s test (intercept = -0.372; P = 0.711). Leave-
one-out sensitivity analysis confirmed that our findings
were not driven by any single study (Figure 4). Robust-
ness of the model was further confirmed by sensitivity
analysis using pooled data from a single marker for each
s t u d y( e i t h e rt h em o s ts p e c i f i co rt h em o s ts e n s i t i v ei n
cases with equal specificity) revealing an overall OR 7.10
(95%CI, 4.21-11.98; I
2 = 0; Figure 3B). Leave-one-out
analysis in the single (prioritized) marker model con-
firmed the lack of a dominant study and the stability of
the pooled calculations (Figure 4B). Subgroup analyses
are presented in Table 3. Tests of interaction did not
detect any significant differences in pooled OR estimates
between the various subgroups (all adjusted P > 0.4).
Discussion
Despite the growing enthusiasm for the use of CTC
molecular detection in bladder cancer patients [13,54]
the diagnostic efficacy data of these molecular methods
reported to date have been variable. The present study
is the first meta-analysis to estimate pooled diagnostic
accuracy characteristics of CTC detection protocols in
bladder cancer as well as the first report to investigate
systematically associations between CTC serum markers
and disease stage in these patients. Our results suggest
Figure 3 Forest plots of association of circulating tumor cell (CTC) detection with disease stage. Forest plots of overall association of CTC
detection with disease stage were calculated by pooling data from all assays in eligible studies (A) and by pooling data from a single detection
assay per study (B). The size of each square is proportional to sample size. The center of each square and the horizontal line show the odds
ratio (OR) and corresponding 95% confidence intervals (CI), respectively. The center of the diamond indicates overall OR and the ends
correspond to 95%CI.
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Page 9 of 14Figure 4 Sensitivity analyses. One-way sensitivity analysis of pooled data from all assays in the 12 eligible studies (A) and from a single marker
assay from each of the 12 eligible studies (B). Each rectangle represents pooled odds ratio (OR); horizontal lines show corresponding 95%
confidence intervals (CI) after omitting each study.
Table 3 Subgroup analyses of association with disease stage meta-analysis
Parameter Subgroup
a OR
b Parameter Subgroups OR
b
Country of origin Japan (n = 5) 10.48 (4.82 to
22.78; I
2 =0 )
Histologic tumor type TCC (n = 9) 7.91 (4.60 to
13.61; I
2 =0 )
Other (n = 7) 5.20 (2.21 to
12.25; I
2 = 22.7%)
Not reported or TCC+other
components (n = 3)
3.94 (0.35 to
43.85; I
2 = 51.1%)
Cell separation
method
Ficoll-Hypaque centrifugation ±
further methods (n = 5)
5.07 (2.48 to
10.35; I
2 =0 )
Sampling time Pretreatment or ≥7 days
post-chemotherapy (n = 9
8.24 (4.63 to
14.68; I
2 =0 )
CellSearch method (n = 3) 7.43 (1.52 to
36.25; I
2 = 22.4%)
NR or miscellany (n = 3) 3.95 (0.36 to
43.95; I
2 = 71.0%)
Other protocols or NR (n = 4) 13.57 (5.27 to
34.95; I
2 =0 )
Blood sample
volume
≤7.5 ml (n = 6) 9.36 (4.65 to
18.86; I
2 =0 )
Collection of two
consecutive blood
samples
Yes (n = 4) 4.25 (1.56 to
11.62; I
2 = 21.1%)
> 7.5 ml (n = 6) 5.00 (2.27 to
11.00; I
2 =0 )
No (n = 8) 9.53 (4.88 to
18.62; I
2 =0 )
Molecular
detection
technique
RT-PCR based (including nested
RT-PCR; n = 7)
8.36 (4.62 to
15.13; I
2 =0 )
Nested RT-PCR method Yes (n = 6) 7.53 (4.09 to
13.85; I
2 =0 )
Other (n = 5) 4.55 (1.07 to
19.35; I
2 = 34.7%)
No (n = 6) 7.21 (1.66 to
31.28; I
2 = 47.0%)
PCR marker
used
c
CK-20 (n = 5) 5.47 (2.80 to
10.68; I
2 =0 )
UP II (n = 3) 1.59 (0.10 to
25.27; I
2 = 89.8%)
Other (n = 3) 17.50 (3.98 to
77.03; I
2 =0 )
aPooled analysis was performed by including the results of single marker (either the most specific or the most sensitive in cases with equal specificity) in cases
where multiple markers were assessed per study.
bData in parentheses are 95% confidence intervals.
cSubgroup analyses of the different tumor markers used in PCR-based methods included and compared data from all markers in those studies where multiple
assays were used.
NR, not reported/retrievable; OR, odds ratio; RBC, red blood cells.
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Page 10 of 14that bladder cancer (and other urothelial cancer) CTC
detection assays have limited diagnostic sensitivity
because they fail to identify approximately two thirds of
patients and show moderate positive and negative diag-
nostic likelihood ratios. On the other hand, CTC detec-
tion demonstrated high specificity for diagnosis of
bladder and other urothelial cancers. Therefore CTC
detection may have limited value as first-line screening
or diagnostic test but may be useful in confirming the
cancer diagnosis.
It should be noted that although significant evidence
for the presence of a threshold effect was not detected,
significant heterogeneity was present among the studies
used in the estimation of diagnostic accuracy variables.
Subgroup analysis showed that studies performed in
Italy yielded significantly higher overall sensitivity esti-
mates. Furthermore, studies conducted in locations
other than Germany, Italy, Japan, and the USA demon-
strated significantly lower overall specificity compared
with that yielded in the four countries where the major-
ity of CTC detection investigations have been per-
formed. These findings should be further elucidated by
multicenter trials as well as standardization of the tech-
niques via collaboration of international centers.
Interestingly, studies reporting urothelial cancer histol-
ogy yielded significantly lower overall sensitivity and
specificity compared those that did not report the histo-
logical type of the investigated bladder cancer. The very
low prevalence of nonurothelial cancer of the urinary
bladder [3] suggests that the vast majority of the bladder
malignancies assessed in the latter studies were of
urothelial cell origin. However, further trials will be
required to investigate the possibility that CTCs from
primary nonurothelial bladder tumor may be more
accurately detected compared with urothelial cancer
using current CTC detection protocols.
An important aspect in CTC detection is the timing of
the assessment because it has been suggested that surgi-
cal interventions may cause transient dissemination of
CTCs in the bloodstream [55,56] whereas chemotherapy
and other systemic treatments may destroy CTCs or
downregulate marker expression and thus convert CTC
+ patients to CTC- [57]. Our findings suggest that non-
treated patients or patients who were assessed ≥7d a y s
after the last treatment were less likely to have detect-
able bladder/urothelial CTCs in their bloodstream. As
expected, collection of two different blood samples and
discarding the first blood tube to avoid cellular contami-
nants such as Merkel cells deriving from skin signifi-
cantly improved the specificity of CTC detection assays
without affecting diagnostic sensitivity. We therefore
recommend implementation of this approach particu-
larly when RT-PCR-based techniques for detection of
epithelial tumor markers are used. On the other hand,
there was no detectable superiority with regards to diag-
nostic accuracy among the various cell enrichment tech-
niques utilized prior to CTC detection. It should also be
noted that despite the good in vitro sensitivity reported
by the majority of studies (Additional file 1) CTC detec-
tion diagnostic accuracy was significantly higher in stu-
dies in which larger blood volumes were drawn. Taking
into account the limited diagnostic sensitivity of CTC
detection assays the detection limit of molecular meth-
ods should be considerably increased to allow efficient
capture of CTCs in < 7.5 ml blood.
Notably, RT-PCR-based protocols yielded significantly
lower sensitivity compared with other molecular detec-
tion approaches and nested RT-PCR methods in parti-
cular demonstrated significantly lower specificity.
Although PCR tests do offer considerable specificity via
the design of primers that are specific to the gene of
interest, the specificity of PCR amplification may be
compromised by a number of factors including sample
contamination, illegitimate transcription (defined as low-
level ubiquitous transcription of tissue-specific genes),
and processed pseudogenes, which are gene sequences
lacking introns that were inserted into the nuclear gen-
ome via mRNA retrotransposition [13,58]. The sensitiv-
ity of PCR assays may also be affected by several factors
including primer selection, PCR conditions used, and
variable expression patterns of investigated tumor mar-
kers among tumors or even CTC clones. These limita-
tions may be addressed by the use of multimarker PCR
assays. Serial testing of RT-PCR-based CTC detection
protocols (whereby detection of all markers tested is
required to designate a sample as CTC+) may thus
improve specificity while parallel testing, considered
positive if any of the markers is detected, may increase
sensitivity. It is of note that only four of the PCR-based
studies used in our meta-analyses calculations
[37,39,45,50] assessed mRNA expression of more than
one marker and only two of these studies provided data
using multimarker combinations [45,50]. Furthermore,
although several bladder cancer molecular markers have
been identified to date [59] no single available marker
(or marker combination) has been determined optimal
for bladder/urothelial CTC detection. There is thus con-
siderable heterogeneity in tumor markers used and only
3 markers (CK-20, UP II, and EGFR) have been investi-
gated in ≥2 studies included in the present meta-analy-
sis. We performed subgroup analyses to compare the
diagnostic accuracy of different PCR-based tumor mar-
ker detection protocols and found that EGFR demon-
strated the highest diagnostic sensitivity compared with
all other markers tested whereas UP II yielded strong
overall specificity that was significantly higher compared
with all other markers other than CK-20 and EGFR.
Further studies are required to corroborate these
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Page 11 of 14findings and to determine the optimal marker combina-
tions for CTC detection in bladder cancer patients.
Current staging systems may inadequately guide thera-
peutic management of bladder cancer since many
patients initially thought to have localized disease may
be upstaged following operative pathology evaluation.
Detection of CTCs may aid in risk stratification and
treatment of bladder or other urothelial cancer patients.
However, the results reported to date have been vari-
able. The present meta-analysis showed that CTC+
bladder/urothelial cancer patients are significantly more
likely to have extra-organ and/or metastatic disease; this
key finding was consistently observed throughout subse-
quent subgroup analyses. This association indicates that
CTC assessment can be used to identify patients who
are more likely to be upstaged to stage III-IV cancer
despite initial clinical classification into locally confined
(stage ≤II) disease and who may be more likely to bene-
fit from neoadjuvant chemotherapy. Only 4 of the 21
studies included in our meta-analyses provided data on
the relation between CTC detection and progression-
free survival whereas 1 of 21 studies investigated the
association of CTC positivity with overall survival.
Future studies should be performed to gain better
knowledge in this area.
A potential limitation of the present meta-analysis is
the considerable degree of interstudy heterogeneity
observed. This issue was addressed by adoption of the
more conservative random effects model to estimate
the weights applied to each effect size as well as by fol-
lowing a rigorous methodological approach that
excluded all studies with < 20 patients or < 30 patients
and controls and required ≥3 studies per subgroup to
p e r f o r mp o o l e ds u b g r o u pa n a lyses. In addition, several
subgroup and sensitivity analyses were performed to
identify and address potential sources of bias. There
was also some variation in the definition of healthy
controls used in the studies, which may influence diag-
nostic accuracy results. However, the rate of false posi-
tive results was similar between different control
groups such as healthy volunteers and cystitis patients
in studies that investigated more than one control
group (Table 1). It should also be noted that LR+
should be interpreted with caution because many stu-
dies reported zero positive CTC tests in the control
groups. In such cases the denominator in the respec-
tive LR+ calculation would be zero. We addressed this
issue by implementing a continuity correction of 0.5 to
these control groups. However, some of the studies
included only a small control population with 4 of 18
studies evaluating < 10 control subjects. In these cases
the continuity correction itself may distort the LR+
calculation. In contrast, these considerations do not
apply to LR- estimates.
Conclusions
In conclusion, our results have highlighted the potential
clinical role of CTC detection as an indicator of
advanced bladder cancer. Our findings suggest that
CTC evaluation may not be used as first-line screening
test. However, the high overall specificity and consistent
significant overall association with disease stage indicate
the potential importance of CTC detection as a quick
and noninvasive method for confirming the cancer diag-
nosis and as a mode of initial cancer staging. Future stu-
dies should determine the optimal tumor markers and
molecular methods for CTC detection, standardize the
available techniques, investigate the potential advantages
of multiple marker assays in PCR-based protocols, and
assess the potential correlation of CTC positivity with
patient survival.
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